| __timestamp | Amicus Therapeutics, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 189101000 |
| Thursday, January 1, 2015 | 76943000 | 96351000 |
| Friday, January 1, 2016 | 104793000 | 95967000 |
| Sunday, January 1, 2017 | 149310000 | 112171000 |
| Monday, January 1, 2018 | 270902000 | 182257000 |
| Tuesday, January 1, 2019 | 286378000 | 336964000 |
| Wednesday, January 1, 2020 | 308443000 | 547851000 |
| Friday, January 1, 2021 | 272049000 | 693716000 |
| Saturday, January 1, 2022 | 276677000 | 891813000 |
| Sunday, January 1, 2023 | 152381000 | 1044071000 |
| Monday, January 1, 2024 | 910408000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Exelixis has consistently outpaced Amicus, with its R&D expenses growing by over 450%, peaking at $1.04 billion in 2023. In contrast, Amicus's R&D spending saw a more modest increase of approximately 220%, reaching its highest point in 2020 with $308 million. This divergence highlights Exelixis's aggressive push towards expanding its research capabilities, while Amicus adopts a more measured approach. As the biotech landscape evolves, these spending patterns may offer insights into each company's future growth and innovation potential.
R&D Insights: How Novartis AG and Exelixis, Inc. Allocate Funds
Comparing Innovation Spending: Amgen Inc. and Exelixis, Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
Research and Development Investment: Pharming Group N.V. vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: ADMA Biologics, Inc. vs Amicus Therapeutics, Inc.
Research and Development Investment: Amicus Therapeutics, Inc. vs Viridian Therapeutics, Inc.